The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.
 
Sawsan Rashdan
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Cardinal Health; Curio Science; G1 Therapeutics; Oncohost; Takeda; Triptych Health Partners
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Cardinal Health; Catalyst Pharmaceuticals; Curio Science; G1 Therapeutics; Oncohost; Takeda
Research Funding - AstraZeneca (Inst)
 
Sagus Sampath
No Relationships to Disclose
 
Puneeth Iyengar
Consulting or Advisory Role - AstraZeneca
Research Funding - Incyte (Inst)
 
Jonathan Dowell
Consulting or Advisory Role - AstraZeneca; Catalyst Pharmaceuticals; Mirati Therapeutics; Takeda
Research Funding - Mirati Therapeutics (Inst)
 
Chul Ahn
Leadership - Psomagen
Stock and Other Ownership Interests - Psomagen
Consulting or Advisory Role - Advarra; Chong Kun Dang Pharmaceutical; IQVIA; LSK Global; PPD Global; Syneos Health
Speakers' Bureau - LSK Global
 
Kenneth D. Westover
Employment - University of Texas Southwestern Medical Center - Simmons Cancer Center
Leadership - Velorum Therapeutics
Stock and Other Ownership Interests - Velorum Therapeutics; Vibliome Therapeutics
Honoraria - Sanofi
Consulting or Advisory Role - Sanofi
 
Yuanyuan Zhang
Research Funding - AstraZeneca
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Clovis Oncology; Dendreon; Foundation Medicine; Gilead Sciences; Janssen Scientific Affairs; Myovant Sciences; Procept Biorobotics; Progenics; Seagen
 
Erminia Massarelli
Honoraria - AstraZeneca; Physicans' Education Resource
Consulting or Advisory Role - Abbvie; Bristol Myers Squibb Foundation; Daiichi-Sankyo; Fusion Pharmaceuticals; Gilead Sciences; Iovance Biotherapeutics; Janssen Scientific Affairs; Mirati Therapeutics; Sanofi
Travel, Accommodations, Expenses - Physicans' Education Resource
 
Arya Amini
Speakers' Bureau - AstraZeneca; Takeda
Research Funding - Genentech
 
Marianna Koczywas
No Relationships to Disclose
 
David E Gerber
Stock and Other Ownership Interests - Gilead Sciences; Walgreens
Consulting or Advisory Role - Catalyst Pharmaceuticals; Daichi Sankyo; Elevation Oncology; Janssen Oncology; Jazz Pharmaceuticals; Regeneron; Sanofi
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst); Novocure (Inst)
Patents, Royalties, Other Intellectual Property - Co-founder, Chief Scientific Officer, OncoSeer Diagnostics, LLC; Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.; UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 4153 - US Patent Application 63/386,387 IMMUNOTHERAPY TOXICITY – CELL PHENOTYPES; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4287 – US Patent Application TBD INNATE AND ADAPTIVE IMMUNE FEATURES ASSOCIATED WITH TOXICITIES IN PATIENTS RECEIVING CHECKPOINT INHIBITOR THERAPY
Other Relationship - OncoSeer Diagnostics
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb